Agios Pharmaceuticals (AGIO) Q2 FY26 earnings call

Agios Pharmaceuticals reported a strong second quarter, driven by robust commercial execution for AQVESME in thalassemia and significant pipeline progress, including the in-licensing of cevidoplenib and advancing Mitapivat for sickle cell disease with a November 1 PDUFA date. The company is strategically diversifying its rare hematology portfolio while maintaining a strong financial position, positioning it for long-term growth despite anticipated shifts in launch dynamics for AQVESME.